Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Videos|May 27, 2020
To Care for Our Patients, We Must Take Care of Ourselves
Author(s)Jessica A. Gold, MD, MS
Dr Jessi Gold provides quick tips for health care professionals to practice self-care during this difficult time.
Advertisement
Dr Jessi Gold provides quick tips for health care professionals to practice self-care during this difficult time.
Dr Gold is Assistant Professor of Psychiatry,
Twitter:
Advertisement
Related to this article
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
4
Should Postpartum Psychosis Be Included in the DSM?
5